Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium, Inc. (Nasdaq: EQ) announced that CEO Bruce Steel and CMO Krishna Polu, M.D., will present at two investor conferences in November 2020. The first event is the Stifel 2020 Virtual Healthcare Conference on November 18 at 3:20 PM ET, followed by the Jefferies Virtual London Healthcare Conference on November 19 at 6:10 PM GMT. Live webcasts will be accessible on Equillium's website, with replays available for 30 days. The company is focused on developing its lead product, itolizumab, for various severe autoimmune diseases.
Equillium, a clinical-stage biotechnology company, released positive interim results from its Phase 1b EQUATE trial of itolizumab for treating acute graft-versus-host disease (aGVHD). The trial reported an 80% overall response rate across cohorts, with a 100% complete response in cohort 3. The firm plans to engage the FDA for expedited pathways for itolizumab, which has already received fast track and orphan drug designations. The complete response rate significantly exceeds standard steroid treatments, highlighting the potential of itolizumab as a life-saving therapy for aGVHD patients.
Equillium, Inc. (Nasdaq: EQ) announced promising data on its drug, itolizumab, for treating systemic lupus erythematosus and lupus nephritis. Presented at the 2020 American College of Rheumatology Virtual Convergence on November 7, the studies show that modulating the CD6-ALCAM pathway improved kidney and skin pathology in mouse models. Experts believe this pathway plays a crucial role in autoimmune diseases, suggesting that targeting it could yield effective treatments for lupus nephritis, a condition with no FDA-approved therapies.
Equillium plans to commence a global Phase 3 COVID-19 trial, named EQUINOX, in Q4 2020, following FDA approval. This study will assess the efficacy of itolizumab in hospitalized patients suffering from acute respiratory distress syndrome (ARDS). Enrolling 800 patients, the trial will evaluate recovery rates, mortality, and safety profiles, with initial data expected by mid-2021. The company aims to address critical healthcare needs amid the COVID-19 crisis and anticipates that successful outcomes could support a Biologic License Application (BLA).
Equillium, Inc. (Nasdaq: EQ) announced the presentation of data at the European Respiratory Society International Congress 2020, highlighting the potential of the CD6-ALCAM pathway as a therapeutic target in uncontrolled asthma. The findings show that soluble ALCAM levels were elevated in patients with severe asthma. The company’s ongoing clinical development of itolizumab aims to treat moderate-to-severe uncontrolled asthma, emphasizing its role in modulating immune responses. Current asthma treatments are inadequate for many patients, underlining the need for new therapies.
Equillium, Inc. (Nasdaq: EQ) announces the completion of a pre-IND meeting with the FDA regarding its drug itolizumab for COVID-19 treatment. The FDA provided positive feedback, enabling Equillium to finalize a protocol and plan to submit a U.S. IND application in October 2020. The company aims to start a global Phase 3 clinical trial in Q4 2020. Successful outcomes may support a Biologic License Application. This milestone is crucial for Equillium's plan to treat COVID-19 patients, utilizing itolizumab's unique immune-modulating properties.
Equillium, Inc. (Nasdaq: EQ) has announced that CEO Bruce Steel and CMO Krishna Polu will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11 AM ET. The virtual event will feature a live webcast accessible on Equillium's website, with replays available for 30 days. Equillium focuses on developing products for severe autoimmune disorders, with its lead candidate, itolizumab, targeting T cell activity. Itolizumab shows promise in treating cytokine release syndrome in COVID-19 patients and is being explored for other severe conditions.
Equillium, Inc. (Nasdaq: EQ) has completed its underwritten public offering of 5,000,000 shares of common stock, priced at $7.00 per share, raising gross proceeds of $35 million. Joint book-running managers for the offering included Jefferies, SVB Leerink, and Stifel. The offering aims to advance Equillium's clinical development of its monoclonal antibody, itolizumab, which targets severe autoimmune disorders. The SEC has approved the registration statement associated with this offering, and the final prospectus is available on their website.
Equillium, Inc. (Nasdaq: EQ) announced a public offering of 5 million shares at $7.00 per share, with potential proceeds of approximately $35 million. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Funds will support the development of product candidates, potential acquisitions, and general corporate purposes. The closing is anticipated on August 18, 2020. Jefferies, SVB Leerink, and Stifel serve as joint book-running managers.
Equillium, Inc. (Nasdaq: EQ) announced its intention to offer shares of its common stock in an underwritten public offering, aiming to sell shares exclusively from the company. Underwriters may purchase an additional 15% within 30 days. Proceeds will fund development of product candidates, potential acquisitions, and general corporate purposes. Jefferies, SVB Leerink, and Stifel are joint book-running managers. The offering is subject to market conditions, and details will be available in the prospectus supplement filed with the SEC.